B·R·A·H·M·S Biomarkers: Software for Aneuploidy and Neural Tube Defect Screening

Prenatal screening software: B·R·A·H·M·S Fast Screen pre I plus Software for aneuploidy and neural tube defects

Discover our modern, powerful and robust clinical prenatal screening software for trisomies and neural tube defects (NTDs) in the first and second trimester.

 

Thermo Scientific B·R·A·H·M·S Fast Screen pre I plus Software is a CE marked prenatal screening software designed to ensure convenience of data entry, risk calculation and reporting for laboratories with both low and high data throughput. It is designed to be used with Thermo Scientific B·R·A·H·M·S KRYPTOR Instruments and Assays.

Key features

Maximum data security and traceability

  • Software audit option for external quality control
  • Internal audits
  • Missing or out of range data warnings
  • Data validation before report production
  • Automatic saving
  • Four levels of user credentials

Effective management tools

  • Statistic and audit reports
  • Pregnancy outcome requests and follow-up information
  • Database search tool
  • Export data for statistics and research
  • Report printing one by one or in batches
  • Automatic printing, saving, and sending of reports by email
  • Can keep extended patient data for record purposes

High connectivity

  • Manual entry of patient data and connection to KRYPTOR
  • Automatic data transfer via Laboratory Information System (LIS)

First trimester trisomy screening algorithms

B·R·A·H·M·S Fast Screen pre I plus Software comprises first trimester algorithms for trisomy that are based on the Fetal Medicine Foundation UK (FMF) data and are updated with recently published correction factors. In addition, our software also includes the algorithm from the FMF Germany. 

  Trisomies 21, 18 and 13
Time range
  • From 8+0 to 14+0 for biochemistry
  • From 45 mm to 84 mm for ultrasound
Biomarkers
  • PAPP-A
  • Free βhCG
  • PlGF (optional)
Physical markers
  • Nuchal translucency (NT)
  • Nasal bone (NB) (optional)
  • Ductus venosus pulsatility index (DVPI) (optional)
  • Tricuspid regurgitation (TR) (optional)
  • Fetal heart rate (FHR) (optional)

The medians of the B·R·A·H·M·S biochemical markers free βhCG, PAPP-A and PlGF which are included in our software are extremely stable. These medians were established on over 220,000 healthy pregnancies which ensures reproducibility and robustness of the risk calculation.1,2 Therefore, a recalculation of the medians and MoMs over time is not required.

FMF first trimester combined test performances for fetal trisomies

View the FMF first trimester combined test performances for fetal trisomies below.3

  Risk cut-off Detection rate False positive rate
Trisomy 21
(Down’s syndrome)		 1:100 92.1% 4.6%
Trisomy 18
(Edwards' syndrome)		 1:50 94.6% 2.7%
Trisomy 13
(Patau's syndrome)		 1:50

91.1%

 2.7%

Second trimester trisomy and neural tube defect (NTD) screening

The B·R·A·H·M·S Fast Screen pre I plus second trimester algorithm allows calculation of risk for trisomies 21 and 18 with double test (AFP in combination with free βhCG or total hCG) between 14+0 and 19+6.

 

Between 15+0 and 19+6, the AFP concentration can be used as a marker of fetal NTD.

More than just a risk calculation tool for your trisomy and NTD screening

Simple and user-friendly interface available in six languages

Available in English, German, French, Spanish, Italian, and Turkish

References

  1. Concerning free βhCG and PAPP-A medians please refer to D. Wright et al., “First-trimester combined screening for trisomy 21 at 7-14 weeks’ gestation” Ultrasound Obstet. Gynecol., vol. 36, no. 4, pp. 404–411, 2010.
  2. Concerning PlGF medians please refer to P. Pandya et al., “Maternal serum placental growth factor in prospective screening for aneuploidies at 8-13 weeks’ gestation” Fetal Diagn. Ther., vol. 31, no. 2, pp. 87–93, 2012.
  3. M. Santorum, D. Wright, A. Syngelaki, N. Karagioti, and K. H. Nicolaides, “Accuracy of first-trimester combined test in screening for trisomies 21, 18 and 13” Ultrasound Obstet. Gynecol., vol. 49, no. 6, pp. 714–720, Jun. 2017.

Thermo Fisher Scientific products are distributed globally and their uses, applications, indications, claims and availability of products in each country depend on local regulatory marketing authorization status, please consult the Instructions For Use (IFU) available in your country.

 

© 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. B·R·A·H·M·S is a registered trademark of B·R·A·H·M·S GmbH.

 

KRYPTOR is a trademark of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific. Other product names in this document are used for identification purposes; they may be trademarks and/or registered trademarks of their respective companies.